ContractAmending Agreement • December 19th, 2005 • NUCRYST Pharmaceuticals Corp. • Pharmaceutical preparations
[***] indicates that text has been omitted which is the subject of a confidential treatment request. This text has been filed separately with the SEC.
FORM OF REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • December 19th, 2005 • NUCRYST Pharmaceuticals Corp. • Pharmaceutical preparations • Alberta
THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of December [___], 2005, between NUCRYST Pharmaceuticals Corp., a corporation incorporated under the laws of Alberta, Canada (the “Company”), and The Westaim Corporation, a corporation incorporated under the laws of Alberta, Canada (“Westaim”).
ContractLicense and Development Agreement • December 19th, 2005 • NUCRYST Pharmaceuticals Corp. • Pharmaceutical preparations • Alberta
[***] indicates that text has been omitted which is the subject of a confidential treatment request. This text has been filed separately with the SEC.
Re: - Amended and Restated License and Development Agreement made as of February 20, 2002 (“License and Development Agreement”) - Distribution in JapanNUCRYST Pharmaceuticals Corp. • December 19th, 2005 • Pharmaceutical preparations
This letter agreement is to confirm that the Japanese Distribution Agreement (as defined in the License and Development Agreement) is to be terminated and as a result thereof, upon such termination, S&N will be entitled to exercise the rights provided for in the License and Development Agreement in relation to Japan as if the exceptions with respect thereto were not included in the License and Development Agreement, all in accordance with the terms and conditions set out in this letter agreement.
NUCRYST PHARMACEUTICALS CORP. FORM OF STOCK OPTION AWARD AGREEMENTStock Option Award Agreement • December 19th, 2005 • NUCRYST Pharmaceuticals Corp. • Pharmaceutical preparations • Alberta
ContractSupply Agreement • December 19th, 2005 • NUCRYST Pharmaceuticals Corp. • Pharmaceutical preparations • Alberta
[***] indicates that text has been omitted which is the subject of a confidential treatment request. This text has been filed separately with the SEC.
ContractAsset Purchase Agreement • December 19th, 2005 • NUCRYST Pharmaceuticals Corp. • Pharmaceutical preparations • Alberta
[***] indicates that text has been omitted which is the subject of a confidential treatment request. This text has been filed separately with the SEC.
NUCRYST PHARMACEUTICALS CORP. • Common Shares UNDERWRITING AGREEMENTUnderwriting Agreement • December 19th, 2005 • NUCRYST Pharmaceuticals Corp. • Pharmaceutical preparations • New York
NUCRYST Pharmaceuticals Corp., an Alberta corporation (the “Company”), and The Westaim Corporation, an Alberta corporation (the “Parent”), confirm their respective agreements with Jefferies & Company, Inc. (“Jefferies”) and each of the other Underwriters named in Exhibit A hereto (collectively, the “Underwriters,” which term shall also include any underwriter substituted as hereinafter provided in Section 10 hereof), for whom Jefferies is acting as representative (in such capacity, the “Representative”), with respect to the issue and sale by the Company of a total of • common shares (the “Initial Securities”) in the capital of the Company (the common shares in the capital of the Company are hereafter called the “Common Shares”), and the purchase by the Underwriters, acting severally and not jointly, of the respective numbers of Initial Securities set forth in said Exhibit A hereto, and with respect to the grant by the Company to the Underwriters, acting severally and not jointly, of th
